Glargine Promotes Proliferation of Breast Adenocarcinoma Cell Line MCF-7 via AKT Activation

被引:22
作者
Teng, J. -A. [2 ]
Hou, R. -L. [3 ]
Li, D. -L. [3 ]
Yang, R. -P. [2 ]
Qin, J. [1 ]
机构
[1] Hosp Guangxi Zhuang Autonomous Reg, Ctr Clin Canc, Dept Radiat Oncol, Nanning 530021, Guangxi, Peoples R China
[2] Hosp Guangxi Zhuang Autonomous Reg, Dept Cadre Med, Nanning 530021, Guangxi, Peoples R China
[3] Xinxiang Med Univ, Dept Physiol & Neurobiol, Xinxiang, Henan, Peoples R China
关键词
glargine; apoptosis; cancer; AKT; INSULIN ANALOGS; RECEPTOR; CANCER; PHOSPHORYLATION; MALIGNANCIES; APOPTOSIS; RISK;
D O I
10.1055/s-0031-1280780
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glargine is widely used as a long-acting insulin analogue in the treatment of diabetes mellitus. However, this insulin analogue has been recently suspected to be associated with an increased risk of cancer. The aim of this study was to investigate the influence of glargine on proliferation of breast adenocarcinoma cell line (MCF-7) and its possible mechanism. Effects of glargine and regular human insulin on the cell proliferation were tested in ER-positive MCF-7 cells by MTT assay. Apoptosis in MCF-7 cells was measured by flow cytometry. The protein levels of p-AKT, Bcl-2, and Bax were also determined by Western blotting and immunohistochemistry, respectively. The result showed that glargine (100, 200 nmol/l) stimulated proliferation of ER-positive MCF-7 cells compared with regular human insulin. At the same time, glargine decreased the percentage of early apoptosis in MCF-7 cells. Otherwise, glargine (100 nmol/l) stimulated the p-AKT in a time-dependent manner in MCF-7 cells. Furthermore, we found that glargine downregulated the level of Bax protein and upregulated that of Bcl-2 (p <0.05). These data show that glargine promote the proliferation of breast adenocarcinoma cells in vitro, probably by preventing apoptosis.
引用
收藏
页码:519 / 523
页数:5
相关论文
共 25 条
[1]   Life-or-death decisions by the Bcl-2 protein family [J].
Adams, JM ;
Cory, S .
TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (01) :61-66
[2]   Effects of polysaccharides of the Euphoria Longan (Lour.) Steud on focal cerebral ischemia/reperfusion injury and its underlying mechanism [J].
Chen, Jian ;
Chen, Xu ;
Qin, Jian .
BRAIN INJURY, 2011, 25 (03) :292-299
[3]   Review on the In Vitro Interaction of Insulin Glargine with the Insulin/Insulin-like Growth Factor System: Potential Implications for Metabolic and Mitogenic Activities [J].
Ciaraldi, T. P. ;
Sasaoka, T. .
HORMONE AND METABOLIC RESEARCH, 2011, 43 (01) :1-10
[4]   The BCL2 family: Regulators of the cellular life-or-death switch [J].
Cory, S ;
Adams, JM .
NATURE REVIEWS CANCER, 2002, 2 (09) :647-656
[5]   Risk of cancer in patients receiving insulin glargine [J].
Dawson, Leslie K. ;
Hamilton, Leslie A. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (23) :2025-2031
[6]   Proliferation of Colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine [J].
Erbel, Saskia ;
Reers, Christina ;
Eckstein, Volker W. ;
Kleeff, Joerg ;
Buechler, Markus W. ;
Nawroth, Peter P. ;
Ritzel, Robert A. .
DIABETES CARE, 2008, 31 (06) :1105-1111
[7]   Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study [J].
Hemkens, L. G. ;
Grouven, U. ;
Bender, R. ;
Guenster, C. ;
Gutschmidt, S. ;
Selke, G. W. ;
Sawicki, P. T. .
DIABETOLOGIA, 2009, 52 (09) :1732-1744
[8]   Drug therapy: Insulin analogues [J].
Hirsch, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (02) :174-183
[9]   Combined randomised controlled trial experience of malignancies in studies using insulin glargine [J].
Home, P. D. ;
Lagarenne, P. .
DIABETOLOGIA, 2009, 52 (12) :2499-2506
[10]   Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden [J].
Jonasson, J. M. ;
Ljung, R. ;
Talback, M. ;
Haglund, B. ;
Gudbjornsdottir, S. ;
Steineck, G. .
DIABETOLOGIA, 2009, 52 (09) :1745-1754